Literature DB >> 31724838

Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.

Laween Uthman1, Anna Homayr1,2, Rio P Juni3, Eva L Spin1, Raphaela Kerindongo1, Marleen Boomsma1, Markus W Hollmann1, Benedikt Preckel1, Pieter Koolwijk3, Victor W M van Hinsbergh3, Coert J Zuurbier1, Martin Albrecht2, Nina C Weber4.   

Abstract

BACKGROUND/AIMS: Heart failure is characterized by chronic low-grade vascular inflammation, which in itself can lead to endothelial dysfunction. Clinical trials showed reductions in heart failure-related hospitalizations of type 2 diabetic patients using sodium glucose co-transporter 2 inhibitors (SGLT2i's). Whether and how SGLT2i's directly affect the endothelium under inflammatory conditions is not completely understood. The aim of the study was to investigate whether the SGLT2i Empagliflozin (EMPA) and Dapagliflozin (DAPA) reduce tumor necrosis factor α (TNFα) induced endothelial inflammation in vitro.
METHODS: Human coronary arterial endothelial cells (HCAECs) and human umbilical vein endothelial cells (HUVECs) were (pre-)incubated with 1 µM EMPA or DAPA and subsequently exposed to 10 ng/ml TNFα. ROS and NO were measured using live cell imaging. Target proteins were either determined by infrared western blotting or fluorescence activated cell sorting (FACS). The connection between Cav-1 and eNOS was determined by co-immunoprecipitation.
RESULTS: Nitric oxide (NO) bioavailability was reduced by TNFα and both EMPA and DAPA restored NO levels in TNFα-stimulated HCAECs. Intracellular ROS was increased by TNFα, and this increase was completely abolished by EMPA and DAPA in HCAECs by means of live cell imaging. eNOS signaling was significantly disturbed after 24 h when cells were exposed to TNFα for 24h, yet the presence of both SGLT2is did not prevent this disruption. TNFα-induced enhanced permeability at t=24h was unaffected in HUVECs by EMPA. Similarly, adhesion molecule expression (VCAM-1 and ICAM-1) was elevated after 4h TNFα (1.5-5.5 fold increase of VCAM-1 and 4-12 fold increase of ICAM-1) but were unaffected by EMPA and DAPA in both cell types. Although we detected expression of SGLT2 protein levels, the fact that we could not silence this expression by means of siRNA and the mRNA levels of SGLT2 were not detectable in HCAECs, suggests aspecificity or our SGLT2 antibody and absence of SGLT2 in our cells.
CONCLUSION: These data suggest that EMPA and DAPA rather restore NO bioavailability by inhibiting ROS generation than by affecting eNOS expression or signaling, barrier function and adhesion molecules expression in TNFα-induced endothelial cells. Furthermore, the observed effects cannot be ascribed to the inhibition of SGLT2 in endothelial cells. © Copyright by the Author(s). Published by Cell Physiol Biochem Press.

Entities:  

Keywords:  SGLT2 inhibitors; Inflammation; Endothelial cell; Empagliflozin; TNFα

Mesh:

Substances:

Year:  2019        PMID: 31724838     DOI: 10.33594/000000178

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  43 in total

Review 1.  Future perspective in diabetic patients with pre- and post-capillary pulmonary hypertension.

Authors:  Federico Luongo; Cristiano Miotti; Gianmarco Scoccia; Silvia Papa; Giovanna Manzi; Nadia Cedrone; Federica Toto; Claudia Malerba; Gennaro Papa; Annalisa Caputo; Giulia Manguso; Francesca Adamo; Dario Vizza Carmine; Roberto Badagliacca
Journal:  Heart Fail Rev       Date:  2022-01-31       Impact factor: 4.214

Review 2.  Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?

Authors:  Christian A Schneider; Roman Pfister
Journal:  Herz       Date:  2022-08-26       Impact factor: 1.740

Review 3.  Endothelial response to glucose: dysfunction, metabolism, and transport.

Authors:  Alisa Morss Clyne
Journal:  Biochem Soc Trans       Date:  2021-02-26       Impact factor: 5.407

4.  Dapagliflozin attenuates cholesterol overloading-induced injury in mice hepatocytes with type 2 diabetes mellitus (T2DM) via eliminating oxidative damages.

Authors:  Liu Yang; Dan Liu; Hongqin Yan; Kaixia Chen
Journal:  Cell Cycle       Date:  2022-01-31       Impact factor: 4.534

Review 5.  Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations.

Authors:  Dimitrios A Vrachatis; Konstantinos A Papathanasiou; Konstantinos E Iliodromitis; Sotiria G Giotaki; Charalampos Kossyvakis; Konstantinos Raisakis; Andreas Kaoukis; Vaia Lambadiari; Dimitrios Avramides; Bernhard Reimers; Giulio G Stefanini; Michael Cleman; Georgios Giannopoulos; Alexandra Lansky; Spyridon G Deftereos
Journal:  Drugs       Date:  2021-07-23       Impact factor: 9.546

Review 6.  Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis.

Authors:  Xiaoling Li; Nina C Weber; Danny M Cohn; Markus W Hollmann; J Hans DeVries; Jeroen Hermanides; Benedikt Preckel
Journal:  J Clin Med       Date:  2021-05-29       Impact factor: 4.241

7.  Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species.

Authors:  Xiaoling Li; Gregor Römer; Raphaela P Kerindongo; Jeroen Hermanides; Martin Albrecht; Markus W Hollmann; Coert J Zuurbier; Benedikt Preckel; Nina C Weber
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

Review 8.  The glomerular filtration barrier: a structural target for novel kidney therapies.

Authors:  Ilse S Daehn; Jeremy S Duffield
Journal:  Nat Rev Drug Discov       Date:  2021-07-14       Impact factor: 84.694

Review 9.  The Role of SGLT2 Inhibitors in Vascular Aging.

Authors:  Le Liu; Yu-Qing Ni; Jun-Kun Zhan; You-Shuo Liu
Journal:  Aging Dis       Date:  2021-08-01       Impact factor: 6.745

Review 10.  Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms.

Authors:  Lei Xiao; Xin Nie; Yanyan Cheng; Nanping Wang
Journal:  Cardiovasc Drugs Ther       Date:  2021-07-17       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.